Europe Movers: Amundi, Assa Abloy, L'Oreal, Novo Nordisk, Siemens Healhineers, Vestas

Inga Muller
06 Feb, 2025
Frankfurt

European markets advanced after investors shifted their focus to a fresh batch of earnings. German factory orders rebounded in December, driven by a surge in volatile transportation orders. 

The DAX index increased by 0.70% to 21,737.00, the CAC-40 index rose 0.69% to 7,946.14, and the FTSE 100 index advanced by 1.13% to 8,721.09. 

The yield on 10-year German bonds inched higher to 2.37%, French bonds increased to 3.09%, the UK gilts moved up to 4.60%, and Italian bonds edged higher to 3.45%.

 

Recent Earnings Movers

Amundi gained 0.3% to €67.35 after the French asset management company beat fourth-quarter expectations on strong net flows and revenue growth.

Revenue increased 14.6% to €924 million from €806 million, net income climbed 17% to €349 million from €299 million, and earnings per share rose 16.7% to €1.70 from €1.46 a year ago.

The company proposed a dividend of €4.25 per share to the annual meeting on March 27, with ex-dividend date on June 10, and payments to begin on June 12.

Vestas Wind Systems A/S surged 8.4% to 109.50 Danish krone after the wind turbine maker reported strong power solutions and services revenues in the fiscal year 2024.

Total revenue increased to €17.29 billion from €15.38 billion, profit surged to €494 million from €78 million, and earnings per diluted share rose to 49 cents from 8 cent a year ago.

Vestas received government grants of €130 million, compared to €56 million last year.

For fiscal 2025, the company estimated revenue of €18 billion to €20 billion, with an EBIT margin before special items of 4% to 7%.

The service segment is expected to grow to €700 million, and the company plans investments of €1.2 billon in 2025.

Vestas proposed a dividend of €75 million, or 7 cents per share (0.55 Danish krone), and also recommended a share buyback of €100 million.

Assa Abloy dropped 1.2% to 329.50 krona despite the Swedish verification systems provider reporting growth in its fourth quarter ending in December.

Revenue increased to SEK 39.57 billion from SEK 36.97 billion, net income jumped to SEK 4.25 billion from SEK 3.98 billion, and earnings per share rose to SEK 3.81 from SEK 3.56 a year ago.

The company’s board proposed a dividend of SEK 5.90 per share, up from SEK 5.40 a year ago, to be distributed in two equal installments.

After the approval by shareholders, the first payment is expected on April 30, and the second payment on November 14.

Novo Nordisk A/S surged 4.5% to 619.50 Danish krone after the pharmaceutical company beat fiscal 2024 profit expectations.

Revenue jumped 25% to DKK 290.4 billion from DKK 232.3 billion, net profit surged 21% to DKK 100.99 billion from DKK 83.68 billion, and earnings per diluted share rose 22% to DKK 22.63 from DKK 18.62 a year ago.

For fiscal 2025, the company estimated sales growth in constant currencies of 19% to 27%, and a loss of DKK 9 billion.

Since February 2024, Novo Nordisk repurchased B shares at DKK 806.37 per B share, for DKK 20 billion.

Arm Holdings Plc plunged 5.4% to €157 after the British advanced chip technologies provider narrowed its full-year forecast.

Revenue in the third quarter of 2025 increased to $983 million from $824 million, net income surged to $252 million from $87 million, and earnings per diluted share rose to 24 cents from 8 cents a year ago.

For the current fiscal fourth quarter, Arm forecast revenue between $1.18 billion and $1.28 billion, with a midpoint of $1.23 billion.

For the full year, Arm narrowed its revenue guidance to a range of $3.94 billion to $4.04 billion from a previous estimate for $3.8 billion to $4.1 billion.

L’Oréal gained 0.2% to €346.40 after the Paris-based cosmetics company agreed to sell approximately 29.6 million of Sanofi shares to Sanofi for €101.5 per share, for a total of €3 billion.

Upon completion of the transaction and cancellation of the repurchased shares, L’Oréal will own 7.2% of Sanofi’s share capital and 13.1% of its voting rights.

Siemens Healthineers AG surged 5.7% to €57.40 after the German medical technology company reported higher-than-expected sales in its first quarter ending in December, despite order delays from China.

Revenue increased 5.9% to €5.48 billion from €5.18 billion, net income jumped 11% to €478 million from €432 million, and basic earnings per share rose 10% to 42 cents from 39 cents a year ago.

In the EMEA, Asia Pacific and Japan regions, revenue rose strongly on a comparable basis, while in the Americas region, sales fell slightly, and in China, sales declined by a mid-single-digit percentage.

Sales in the company’s diagnostics segment rose 1.6% in the first quarter to €1.1 billion, in the Varian segment they were up 6.2% to €1.0 billion, and in the advanced therapies division revenue rose 5.1% to €499 million.

In the imaging segment, adjusted external revenue increased to €2.90 billion from €2.69 billion a year ago.

For fiscal year 2025, the company estimated comparable revenue growth of 5% to 6% year-over-year, and adjusted basic earnings per share of between €2.35 and €2.50.